Findings from First-in-Human Study Support Continued Clinical Development of Investigational IOP-lowering Therapy; New Trials Planned as Complementary Glaucoma Treatment and in Rare Pediatric Indication
WELLESLEY, Mass., May 18, 2022--(BUSINESS WIRE)--Qlaris Bio, Inc. (the "Company" or "Qlaris"), a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, today announced results from QC-201, a first-in-human, Phase 2 clinical trial of QLS-101, the Companys investigational therapy for lowering intraocular pressure (IOP) in the treatment of glaucoma. Study findings demonstrated a favorable safety and tolerability profile for QLS-101, including no evidence of hyperemia (eye redness), as well as a positive efficacy signal, in patients with primary open-angle glaucoma (POAG) or ocular hypertension.
These data support the ongoing clinical development of QLS-101 and Qlaris intends to initiate several new studies designed to further assess the potential role of the compound as a first-in-class glaucoma treatment. Additional clinical trials will seek to evaluate QLS-101 as a complementary therapy to available glaucoma treatments and procedures, such as prostaglandin analogs and minimally invasive glaucoma surgery (MIGS), and as a treatment for juvenile patients with Sturge-Weber syndrome (SWS)-related glaucoma.
QLS-101 is a novel adenosine triphosphate (ATP)-sensitive potassium (KATP) channel modulator administered as a topical eyedrop. Unlike currently available therapies for lowering IOP in glaucoma, QLS-101 targets distal outflow resistance and episcleral venous pressure (EVP), a key component of IOP. QLS-101 improves the outflow of aqueous humor by widening outflow channels and the episcleral vessels of the eye distal to the trabecular meshwork to lower IOP.
"These Phase 2 data are encouraging, particularly the absence of hyperemia, which is a common side effect with certain glaucoma treatments and one which can lead patients to discontinue therapy," said Thurein Htoo, MS, MBA, chief executive officer and co-founder of Qlaris Bio. "With the well-tolerated safety profile and efficacy signal demonstrated in this study, we believe QLS-101 can serve as a compelling complement to existing drugs and drainage devices to help patients for whom EVP and distal outflow resistance may be pathologic or treatment-limiting."
Story continues
"As a clinician, I often see glaucoma patients whose vision loss continues to progress even when treated with current therapeutic options that target different components of IOP than EVP," said Barbara Wirostko, MD, FARVO, chief medical officer and co-founder of Qlaris Bio. "QLS-101 may provide a first-in-class mechanism of action to lower IOP by focusing on resistance distal to the trabecular meshwork of the eye that is not yet fully addressed by available therapies. We look forward to initiating additional studies pursuing these new solutions."
POAG is the most common adult form of glaucoma and remains one of the leading causes of preventable blindness worldwide. Elevated IOP remains the only modifiable risk factor for progression of glaucoma. Despite available therapies and surgical interventions, patients with POAG may not achieve IOP-lowering goals as available options only target three components of IOP. This leaves the fourth component of IOP EVP insufficiently addressed.
"The results from the QC-201 trial are promising and certainly should prompt continued study of the potential impact of this promising investigational therapy," said Sharon F. Freedman, MD, professor of ophthalmology and pediatrics at Duke University Medical Center, and a principal investigator in ongoing Qlaris trials. "An EVP-targeting therapy could also address a significant unmet need for patients living with certain types of glaucoma, such as Sturge-Weber syndrome. I look forward to continued collaboration with Qlaris on this important work."
SWS is a pediatric rare disease signified by a facial port wine birthmark. Individuals living with SWS often suffer from severe, intractable glaucoma in the eye on the same side as their birthmark. In these individuals, increased IOP is driven by pathologically elevated EVP. By directly lowering EVP, QLS-101 may be uniquely well-suited to address SWS and improve therapeutic outcomes.
About QLS-101
QLS-101, Qlaris Bios lead product candidate, is a prodrug of levcromakalim, an adenosine triphosphate (ATP)-sensitive potassium (KATP) channel modulator. By lowering episcleral venous pressure (EVP) and increasing aqueous humor outflow through vessels distal to the trabecular meshwork, QLS-101 may be able to uniquely address diseases of pathologic EVP resulting in elevated intraocular pressure (IOP), such as Sturge-Weber syndrome-related glaucoma, and diseases where EVP limits maximal therapy, including primary open-angle glaucoma and normal-tension glaucoma. QLS-101 was invented at Mayo Clinic and the University of Minnesota and is being developed under an exclusive worldwide license.
About Qlaris Bio, Inc.
Qlaris Bio, Inc. was founded in August 2019 with a singular focus: to develop novel, innovative therapies with first-in-class mechanisms of action to address serious and debilitating ophthalmic diseases. The companys lead platform is based on the use of adenosine triphosphate (ATP)-sensitive potassium (KATP) channel modulators to affect the tone of vascular and vascular-like tissues, initially focused on ophthalmic use. Qlaris Bios investors include Canaan and New Leaf Venture Partners, both of which were co-lead investors in the companys $25 million Series A round in August 2019. Other investors include Correlation Ventures and Mayo Clinic. For more information, please visit qlaris.bio.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005187/en/
Contacts
Media Contact Matt Pera973-886-9150matt.pera@smithsolve.com
Here is the original post:
- Eye exercises for vertigo: Exercises to try at home - Medical News Today - January 6th, 2023
- EMDR therapy: Everything you need to know - Medical News Today - December 28th, 2022
- Eye floaters: What causes them, and what can you do? - Medical News Today - December 28th, 2022
- Eye care professional - Wikipedia - December 28th, 2022
- New gene therapy to treat rare eye disease now available in Alberta ... - December 28th, 2022
- Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol - PR Newswire - August 11th, 2022
- New research digs into the genetic drivers of heart failure, with an eye to precision treatments - STAT - August 11th, 2022
- Gamma Probe Device Market Trends, On-going Demand, Opportunities, Segmentation, and Forecast till 2031 - BioSpace - August 11th, 2022
- Babies born exposed to opioids and drugs need our support - GoErie.com - August 3rd, 2022
- Centrifuge Market: Increasing Prevalence of Infectious Diseases to Drive the Market - BioSpace - August 3rd, 2022
- Myopic macular degeneration: What it is, and more - Medical News Today - July 17th, 2022
- Roche Wraps Week with a Bang, Touting Long-Term Breast Cancer, AMD Data - BioSpace - July 17th, 2022
- EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment... - July 17th, 2022
- What Are These Things Floating in Front of My Eyes? - The Epoch Times - July 17th, 2022
- Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022... - July 17th, 2022
- Retinoblastoma among children: Early detection and treatment are vital - The Financial Express - May 20th, 2022
- Perceive Biotherapeutics Appoints Anne E. Fung MD, as Chief Medical Officer to Drive Transformational Clinical Programs - PR Newswire - May 20th, 2022
- How the Pandemic is Taking a Toll on Rhode Island's Front-Line Health Care Workers - Rhode Island Monthly - May 20th, 2022
- Myrtelle Enters into a Worldwide Exclusive License Agreement with Rescue Hearing to Develop and Commercialize Gene Therapy for the Treatment of... - May 20th, 2022
- Capsida, Adverum, Instil and Metagenomi Showcase Therapies at ASGCT - BioSpace - May 20th, 2022
- GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of... - May 20th, 2022
- How Diabetes can be a driver for High blood pressure and eventually leads to Hypertension - APN News - May 20th, 2022
- Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative - Yahoo Finance - April 11th, 2022
- Christian group prepares legal challenge over conversion therapy ban - The Telegraph - April 11th, 2022
- PFE: 5 Global Healthcare Stocks to Buy as BofA Warns of a - StockNews.com - April 11th, 2022
- Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the... - April 11th, 2022